Blood

Vol. 146, Issue 6 Issue 6 2025
18
Articles

Articles in this Issue

CD24 senescent neutrophils as key players in myelofibrosis

William Vainchenker, Nasrine Yahmi Aug 07, 2025 pp. 653-655 10.1182/blood.2025029658

Defective neutrophil clearance in <i>JAK2</i> <i>V617F</i> myeloproliferative neoplasms drives myelofibrosis via immune checkpoint CD24

Eman Khatib-Massalha, Christian A. Di Buduo, Agathe L. Chédeville et al. Aug 07, 2025 pp. 717-731 10.1182/blood.2024027455

Abstract Myeloproliferative neoplasms (MPNs) are hematopoietic stem cell–driven malignancies marked by excessive myelopoiesis and high risk of myelofibrosis, which remains therapeuti...

Cracking TRALI: targeting the membrane attack complex

Fabrice Cognasse, Hind Hamzeh-Cognasse Aug 07, 2025 pp. 658-660 10.1182/blood.2025029798

Not dead yet: GWAS insights into a common bleeding disorder

Karl C. Desch Aug 07, 2025 pp. 657-658 10.1182/blood.2025029543

Counterpoint: the design and interpretation of blood transfusion randomized clinical trials

Jeffrey L. Carson, Paul C. Hebert, John H. Alexander Aug 07, 2025 pp. 661-666 10.1182/blood.2025029042

Abstract A recent Perspective in Blood suggested that previous evidence from over a decade ago established that a liberal rather than a restrictive blood transfusion strategy results...

Keep your distance or lose control

Gerd A. Blobel Aug 07, 2025 pp. 655-656 10.1182/blood.2025029959

Van Laer C, Lavend’homme R, Baert S, et al. Functional assessment of genetic variants in thrombomodulin detected in patients with bleeding and thrombosis. <i>Blood</i>. 2025;145(17):1929-1942.

Aug 07, 2025 pp. 766-766 10.1182/blood.2025030542

Optimal MRD-based end point to support response-adapted treatment cessation in newly diagnosed multiple myeloma

Smith Giri, Binod Dhakal, Natalie S. Callander et al. Aug 07, 2025 pp. 707-716 10.1182/blood.2024027674

Abstract The therapeutic success of first-line quadruplet (QUAD) induction therapy and autologous stem cell transplantation (ASCT) has reinvigorated an interest in fixed-duration the...

Inhibition of terminal complement complex formation alleviates murine antibody-mediated TRALI

Dawei Chen, Huaqin Liang, Xiuzhang Xu et al. Aug 07, 2025 pp. 759-764 10.1182/blood.2024028012

Abstract Transfusion-related acute lung injury (TRALI) is a leading cause of blood transfusion–triggered mortality. Recently, we demonstrated the critical role of Fc-dependent comple...

Atypical cytoplasmic inclusions and erythrophagocytosis in acute myeloid leukemia with <i>KMT2A</i>::<i>MLLT3</i> and <i>U2AF1</i> mutation

Shuying Chen, Zhijian Xiao Aug 07, 2025 pp. 765-765 10.1182/blood.2025029617

Genome-wide meta-analysis of heavy menstrual bleeding reveals 36 risk loci

Florian Thibord, Jason Cunha, Jelisaveta Džigurski et al. Aug 07, 2025 pp. 745-758 10.1182/blood.2024027382

Abstract Heavy menstrual bleeding (HMB) is a widespread occurrence among women of reproductive age and inflicts a substantial impact on their well-being and on health care expenses....

Sustained MRD negativity: robust, not all-powerful

Aurore Perrot, Jill Corre Aug 07, 2025 pp. 652-653 10.1182/blood.2025029342

Reactivation of developmentally silenced globin genes through forced linear recruitment of remote enhancers

Anna-Karina Felder, Sjoerd J. D. Tjalsma, Han J. M. P. Verhagen et al. Aug 07, 2025 pp. 732-744 10.1182/blood.2024028128

Abstract The human genome contains regulatory DNA elements, known as enhancers, that can activate gene transcription over long chromosomal distances. Here, we showed that enhancer di...

Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results

Jill Corre, Laure Vincent, Philippe Moreau et al. Aug 07, 2025 pp. 679-692 10.1182/blood.2024027620

Abstract Previous results from CASSIOPEIA demonstrated superior progression-free survival (PFS) and minimal residual disease (MRD) negativity with the addition of daratumumab to bort...

Speeding up for lympho-myeloid differentiation

Ingmar Glauche, Artur C. Fassoni Aug 07, 2025 pp. 650-652 10.1182/blood.2025029355

Myeloma: a sky full of MRD stars

Bruno Paiva, Jesus F. San-Miguel Aug 07, 2025 pp. 649-650 10.1182/blood.2025029160

How I treat acute lymphoblastic leukemia in the era of immunotherapy while revisiting the myth of second remission

Ibrahim Aldoss, Mary C. Clark, Stephen J. Forman Aug 07, 2025 pp. 667-678 10.1182/blood.2024027267

Abstract In 2013, we published a Perspective titled “The myth of the second remission of acute leukemia in the adult,” which underscored the dismal outcomes of relapsed acute leukemi...

Coordinated regulation of self-renewal and cell cycle during human lympho-myeloid lineage restriction

Fangwu Wang, Laura Gonzalez, Qiuyu Lian et al. Aug 07, 2025 pp. 693-706 10.1182/blood.2024026936

Abstract Recent studies indicate the human lympho-myeloid restriction process to be a different and more heterogeneous one than historically inferred. Here we describe the developmen...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page